GSK1070916 is a reversible and ATP-competitive inhibitor of Aurora B/C with IC50 of 3.5 nM/6.5 nM and displays > 100-fold selectivity against the closely related Aurora A-TPX2 complex (IC50=490 nM).

MK-5108 is a potent and highly selective Aurora inhibitor with IC50 of 0.064, 14 and 12 nM for Aurora A, B and C.

CCT137690 is a potent inhibitor of Aurora kinases (IC50 values are 0.015, 0.019 and 0.025 μM at Aurora A, Aurora C and Aurora B respectively).

CD532 is a potent Aurora A kinase inhibitor with an IC50 of 45 nM. CD532 has the dual effect of blocking Aurora A kinase activity and driving degradation of MYCN. CD532 also can directly interact with AURKA and induces a global conformational shift. CD532 can be used for the research of cancer.

MLN8054 is a potent and selective inhibitor of Aurora A with IC50 of 4 nM and exhibits more than 40-fold selective for Aurora A than Aurora B.

CCT129202 is a Aurora kinase inhibitor with IC50 of 0.042 ± 0.022, 0.198 ± 0.05, and 0.227 ± 0.064 μM for Aurora A, Aurora B, and Aurora C, respectively.

MK-8745 is a potent and selective Aurora an inhibitor with IC50 of 0.6 nM, more than 450-fold selectivity for Aurora A over Aurora B.

TAK-901 is an inhibitor of Aurora A/B with IC50 of 21 nM/15 nM.

AMG-900 is a potent and highly selective pan-Aurora kinases inhibitor for Aurora A/B/C with IC50 of 5 nM/4 nM /1 nM, and is > 10-fold selective for Aurora kinases than p38α, Tyk2, JNK2, Met and Tie2.

Aurora an inhibitor I is a potent, and selective inhibitor of Aurora A with IC50 of 3.4 nM in a cell-free assay. It is 1000-fold selective for Aurora A than Aurora B.

ZM 447439 is a selective and ATP-competitive inhibitor for Aurora A and Aurora B with IC50 of 110 nM, 130 nM respectively, > 8 fold selectivity than Aurora C, MEK1, Src.

SP-96 is a highly selective and non-ATP-competitive Aurora A/B inhibitor with IC50 values of 0.316nM 18.975 nM for Aurora A and Aurora B, respectively.

Alisertib is a selective Aurora inhibitor with IC50 of 1.2 nM with > 200-fold higher selectivity for Aurora A than Aurora B.

Maleic acid is used in the synthesis of pyridoindolones as potent inhibitors of Aurora kinases. It is a reagent in the preparation of TiO2/carbon nanotube composites.

Reversine, a synthetic purine analogue(2,6-disubstituted purine), is a potent human A3 adenosine receptor antagonist with Ki of 0.66 μM, and a pan-aurora A/B/C kinase inhibitor with IC50 of 12 nM/13 nM/20 nM, respectively.

SU6668 is a cell-permeable indolinone compound that acts as a potent ATP-competitive inhibitor against RTKs (receptor tyrosine kinases) Kit, PDGFRβ, VEGFR2 (Flk-1/KDR), FGFR1 activity in vitro (IC50 = 0.01, 0.1, 3.9, and 3.8 µM, respectively) and PDGF/VEGF/bFGF-mediated angiogenesis and tumor development. Although initially characterized as an RTK inhibitor, SU6668 is now also known to target ser/thr kinases Aurora A, Aurora B, TBK1 (NAK/T2K), and AMPK (IC50 = 0.85, 0.047, 1.4, and 1.8 µM, respectively), as well as non-receptor TKs Lyn and Yes (IC50 = 4.3 and 5.8 µM, respectively).

JNJ-7706621 is a pan-CDK inhibitor that inhibits CDK1/2 with IC50 of 9/4 nM, also potently inhibits Aurora A/B.

Danusertib is a pyrrolo-pyrazole and small molecule Aurora kinases inhibitor with IC50 of 13, 79, and 61 nM for Aurora A, B, and C, respectively. It is modestly potent to Abl, TrkA, c-RET and FGFR1, and less potent to Lck, VEGFR2/3, c-Kit, CDK2, etc.